These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 36085228)
1. EQ-5D-5L measurement properties are superior to EQ-5D-3L across the continuum of health using US value sets. Jiang R; Rand K; Kuharic M; Pickard AS Health Qual Life Outcomes; 2022 Sep; 20(1):134. PubMed ID: 36085228 [TBL] [Abstract][Full Text] [Related]
2. Interim EQ-5D-5L Value Set for Poland: First Crosswalk Value Set in Central and Eastern Europe. Golicki D; Niewada M; Hout BV; Janssen MF; Pickard AS Value Health Reg Issues; 2014 Sep; 4():19-23. PubMed ID: 29702801 [TBL] [Abstract][Full Text] [Related]
3. Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients. Golicki D; Niewada M; Karlińska A; Buczek J; Kobayashi A; Janssen MF; Pickard AS Qual Life Res; 2015 Jun; 24(6):1555-63. PubMed ID: 25425288 [TBL] [Abstract][Full Text] [Related]
4. Interim value set for the EQ-5D-5L in Iran using the Crosswalk method. Ameri H; Safari H; Yousefi M; Bagheri Faradonbeh S; Goudarzi R; Soofi M Med J Islam Repub Iran; 2020; 34():121. PubMed ID: 33437717 [No Abstract] [Full Text] [Related]
5. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets. Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577 [TBL] [Abstract][Full Text] [Related]
6. Mapping Sri Lankan EQ-5D-3L to EQ-5D-5L Value Sets. Kularatna S; Chen G; Byrnes J; Scuffham PA Value Health Reg Issues; 2017 May; 12():20-23. PubMed ID: 28648311 [TBL] [Abstract][Full Text] [Related]
7. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. van Hout B; Janssen MF; Feng YS; Kohlmann T; Busschbach J; Golicki D; Lloyd A; Scalone L; Kind P; Pickard AS Value Health; 2012; 15(5):708-15. PubMed ID: 22867780 [TBL] [Abstract][Full Text] [Related]
8. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter? Yang F; Devlin N; Luo N Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633 [TBL] [Abstract][Full Text] [Related]
9. How the EQ-5D utilities are derived matters in Chinese diabetes patients: a comparison based on different EQ-5D scoring functions for China. Pan CW; Zhang RY; Luo N; He JY; Liu RJ; Ying XH; Wang P Qual Life Res; 2020 Nov; 29(11):3087-3094. PubMed ID: 32533422 [TBL] [Abstract][Full Text] [Related]
10. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study. Hernandez G; Garin O; Dima AL; Pont A; Martí Pastor M; Alonso J; Van Ganse E; Laforest L; de Bruin M; Mayoral K; Serra-Sutton V; Ferrer M; J Med Internet Res; 2019 Jan; 21(1):e10178. PubMed ID: 30672744 [TBL] [Abstract][Full Text] [Related]
11. Crosswalk EQ-5D-5L Value Set for Slovenia. Prevolnik Rupel V; Ogorevc M Zdr Varst; 2020 Sep; 59(3):189-194. PubMed ID: 32952720 [TBL] [Abstract][Full Text] [Related]
12. EQ-5D-5L is More Responsive than EQ-5D-3L to Treatment Benefit of Cataract Surgery. Gandhi M; Ang M; Teo K; Wong CW; Wei YC; Tan RL; Janssen MF; Luo N Patient; 2019 Aug; 12(4):383-392. PubMed ID: 30607809 [TBL] [Abstract][Full Text] [Related]
13. A vision 'bolt-on' increases the responsiveness of EQ-5D: preliminary evidence from a study of cataract surgery. Gandhi M; Ang M; Teo K; Wong CW; Wei YC; Tan RL; Janssen MF; Luo N Eur J Health Econ; 2020 Jun; 21(4):501-511. PubMed ID: 31902023 [TBL] [Abstract][Full Text] [Related]
14. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary. Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242 [TBL] [Abstract][Full Text] [Related]
15. Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets. Mulhern B; Feng Y; Shah K; Janssen MF; Herdman M; van Hout B; Devlin N Pharmacoeconomics; 2018 Jun; 36(6):699-713. PubMed ID: 29476363 [TBL] [Abstract][Full Text] [Related]
16. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. Poór AK; Rencz F; Brodszky V; Gulácsi L; Beretzky Z; Hidvégi B; Holló P; Kárpáti S; Péntek M Qual Life Res; 2017 Dec; 26(12):3409-3419. PubMed ID: 28875430 [TBL] [Abstract][Full Text] [Related]
17. Comparing the properties of the EQ-5D-5L and EQ-5D-3L in general population in Iran. Rezaei S; Woldemichael A; Ahmadi S; Mohamadi Bolbanabad A; Zahir Abdullah F; Piroozi B Int J Health Plann Manage; 2021 Sep; 36(5):1613-1625. PubMed ID: 34013594 [TBL] [Abstract][Full Text] [Related]
18. Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease. Rencz F; Lakatos PL; Gulácsi L; Brodszky V; Kürti Z; Lovas S; Banai J; Herszényi L; Cserni T; Molnár T; Péntek M; Palatka K Qual Life Res; 2019 Jan; 28(1):141-152. PubMed ID: 30225788 [TBL] [Abstract][Full Text] [Related]
19. The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients. Pan CW; Sun HP; Wang X; Ma Q; Xu Y; Luo N; Wang P Qual Life Res; 2015 Jul; 24(7):1767-74. PubMed ID: 25540029 [TBL] [Abstract][Full Text] [Related]
20. The EQ-5D-5L is More Discriminative Than the EQ-5D-3L in Patients with Diabetes in Singapore. Wang P; Luo N; Tai ES; Thumboo J Value Health Reg Issues; 2016 May; 9():57-62. PubMed ID: 27881260 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]